OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

HTML

Year: 2018
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2018-99-119424
Authors: Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Naval G. Daver, Elias J. Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Simona Colla, Hui Yang, Caitlin R. Rausch, Yvonne Gasior, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Keyur P. Patel, Hagop M. Kantarjian
Institution: The University of Texas MD Anderson Cancer Center
Language: English

Topic: Acute Myeloid Leukemia Research
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: myelodysplastic syndrome, nivolumab, ipilimumab, azacitidine, immune checkpoint inhibitors, PD-1, CTLA-4, hypomethylating agents, first-line therapy, resensitization, treatment toxicity, response rate, IPSS risk stratification, prognostic factors
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2906720786
Cites:
Cited by: 78
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security